infecti
diseas
epidem
match
war
natur
disast
capac
threaten
live
damag
economi
like
sar
previous
zika
recent
ebola
crisi
show
vulner
world
epidem
peopl
die
outbreak
addit
caus
immens
human
suffer
epidem
particularli
affect
lowand
middleincom
countri
mani
deadli
infecti
diseas
epidem
potenti
becom
global
health
emerg
absenc
effect
vaccin
vaccin
threat
develop
creat
proven
medic
product
measl
vaccin
effici
live
attenu
replic
viru
safe
administ
billion
children
last
year
afford
lifelong
protect
singl
dose
take
advantag
characterist
attenu
viru
transform
versatil
chimer
recombin
vaccin
vector
demonstr
proofofprincipl
human
preclin
track
record
rapid
adapt
effect
varieti
pathogen
clinic
trial
shown
safeti
immunogen
vaccin
platform
individu
preexist
immun
measl
review
describ
potenti
platform
develop
new
vaccin
emerg
viral
diseas
emerg
viral
diseas
evd
make
headlin
past
two
decad
subsequ
outbreak
emphas
global
lack
prepared
control
minim
spread
diseas
human
anim
popul
burden
evd
public
health
global
economi
massiv
direct
indirect
cost
zoonot
diseas
estim
exceed
us
billion
last
decad
alon
rise
evd
case
trace
number
caus
grow
global
popul
expect
reach
billion
peopl
result
expand
urban
deforest
expos
popul
reservoir
new
virus
furthermor
highdens
live
condit
often
associ
low
qualiti
life
insuffici
health
care
thu
facilit
diseas
transmiss
climat
chang
also
play
major
role
enabl
emerg
infect
new
locat
warmer
weather
increas
rang
arthropod
diseas
vector
mosquito
tick
global
dramat
growth
intern
travel
also
increas
rapid
scale
emerg
diseas
dissemin
particular
concern
top
seven
prioriti
pathogen
design
world
health
organ
like
caus
major
outbreak
associ
high
mortal
rate
due
lack
effect
medic
treatment
countermeasur
pathogen
zoonot
includ
crimeancongo
hemorrhag
fever
viru
cchfv
ebola
marburg
virus
ebov
lassa
viru
lasv
middl
east
respiratori
syndrom
coronaviru
merscov
sever
acut
respiratori
syndrom
coronaviru
sarscov
nipah
viru
niv
rift
valley
fever
viru
rvfv
addit
chikungunya
viru
chikv
zika
viru
zikv
declar
health
emerg
epidem
potenti
despit
low
mortal
rate
mosquitoborn
arbovirus
rapidli
spread
larg
popul
zoonot
virus
transmit
directli
human
anim
reservoir
exampl
niv
acquir
bat
shed
merscov
camel
sarscov
civet
altern
transmiss
occur
intermedi
host
niv
infect
pig
follow
transmiss
pig
human
ebov
transmiss
bat
nonhuman
primat
nhp
human
larger
human
outbreak
subsequ
occur
individu
come
contact
bodi
fluid
urin
saliva
aerosol
droplet
blood
infect
person
air
travel
trade
ship
carri
infect
person
anim
vector
result
intercontinent
spread
diseas
pandem
sever
vaccin
platform
develop
prevent
care
diseas
prepared
futur
outbreak
review
discuss
measl
viru
mv
vector
promis
altern
convent
vaccin
develop
method
strength
vaccin
platform
emerg
diseas
compar
approach
platform
base
replic
mv
vaccin
vector
demonstr
proofofprincipl
human
preclin
track
record
rapid
adapt
effect
varieti
pathogen
tackl
unpredict
regard
evd
aris
requir
strong
intern
diseas
surveil
network
well
commit
develop
prevent
measur
postexposur
treatment
reason
may
world
health
assembl
welcom
develop
blueprint
acceler
research
develop
epidem
health
emerg
situat
insuffici
prevent
cur
solut
take
account
relev
work
stream
within
r
blueprint
aim
reduc
time
declar
intern
public
health
emerg
avail
effect
test
vaccin
antivir
treatment
save
live
avert
public
health
crisi
follow
initi
coalit
epidem
prepared
innov
http
cepinet
creat
cepi
allianc
govern
industri
academia
philanthropi
intergovernment
institut
civil
societi
aim
financ
coordin
develop
new
vaccin
prevent
contain
infecti
diseas
epidem
epidem
disproportion
affect
lowincom
countri
cepi
ensur
vaccin
afford
avail
popul
need
current
drug
avail
effici
treat
acut
viru
infect
viral
inhibitor
ribavirin
other
reduc
slow
viral
replic
give
host
immun
system
chanc
develop
clear
viru
howev
treatment
window
acut
viral
infect
short
symptom
often
appear
late
cours
infect
viral
clearanc
phase
fig
host
becom
infecti
passiv
immun
use
emerg
case
high
exposur
area
seen
ebov
niv
hendra
viru
outbreak
approach
practic
gener
implement
due
high
cost
limit
efficaci
therefor
prophylact
vaccin
remain
simpl
safe
effect
way
prevent
viral
infect
subsequ
outbreak
inde
vaccin
crucial
control
elimin
mani
deadli
viral
diseas
repres
effici
method
prevent
viral
infect
inactiv
kill
virus
live
attenu
virus
subunit
vaccin
compris
convent
mode
vaccin
inactivatedviru
vaccin
made
whole
viru
particl
treat
chemic
heat
radiat
live
attenu
viru
vaccin
creat
passag
virul
viru
strain
anim
cell
cultur
viru
adapt
new
host
longer
pathogen
target
anim
human
usual
passag
inactivatedviru
subunit
vaccin
nonrepl
compet
risk
revers
infect
usual
effect
enough
elicit
strong
host
immun
respons
immun
efficaci
requir
use
adjuv
sever
booster
turn
caus
side
effect
sever
allerg
reaction
hand
live
attenu
vaccin
elicit
longterm
protect
immun
respons
replic
insid
host
howev
depend
number
attenu
mutat
viral
famili
risk
revers
virul
regain
reassort
pathogen
strain
observ
oral
live
polio
vaccin
moreov
convent
attenu
lengthi
process
requir
numer
passag
take
month
sever
year
work
render
impract
prompt
respons
ongo
outbreak
nevertheless
given
efficaci
simpl
administr
regimen
eas
largescal
manufactur
live
attenu
vaccin
remain
attract
choic
vaccin
design
highli
success
exampl
live
attenu
vaccin
includ
develop
smallpox
yellow
fever
poliomyel
measl
latter
three
success
implement
lowand
middleincom
countri
expand
program
immun
epi
welltest
effect
live
attenu
viru
vaccin
modifi
modern
recombin
dna
technolog
combin
advantag
replic
viral
vector
need
rapid
method
develop
new
vaccin
emerg
reemerg
diseas
live
replic
vector
mv
vector
character
induct
longliv
protect
immun
one
two
administr
revers
genet
technolog
viral
vector
vaccin
platform
creat
carri
antigen
protein
anoth
circul
viru
yield
vaccin
candid
quickli
test
establish
anim
model
plugandplay
platform
capac
provid
rapid
respons
futur
emerg
viral
diseas
rang
nm
due
flexibl
envelop
structur
insid
particl
genom
viral
rna
tightli
wrap
n
p
l
constitut
helicoid
ribonucleoprotein
rnp
complex
autorepl
host
cytoplasm
rnp
serv
templat
viral
rna
synthesi
n
molecul
associ
nucleotid
effici
replic
requir
genom
length
respect
socal
rule
six
mean
total
number
genom
nucleotid
divid
sinc
helicoid
structur
highli
flexibl
like
spring
genom
toler
larg
insert
long
total
length
compli
rule
six
viral
gene
transcrib
success
n
l
gene
polymeras
stop
restart
intergen
region
howev
effici
reiniti
mrna
produc
decreas
amount
end
genom
result
greatest
abund
n
lowest
abund
l
protein
accumul
intracellular
n
protein
promot
shift
transcript
replic
replic
l
synthes
complet
copi
entir
genom
positivesens
antigenom
serv
templat
gener
fulllength
negativesens
genom
packag
viral
particl
assembl
n
p
l
protein
synthes
cytoplasm
bud
plasma
membran
togeth
envelop
protein
local
surfac
membran
live
attenu
mv
vaccin
one
safest
effect
vaccin
avail
sever
mv
vaccin
strain
schwarzmoraten
edmonstonzagreb
aikc
strain
develop
pathogen
wildtyp
viru
multipl
passag
variou
cellular
substrat
chicken
egg
chicken
embryo
fibroblast
differ
condit
past
year
mv
vaccin
administ
safe
billion
children
case
revers
report
induc
humor
cellular
immun
respons
effici
stimul
longlast
memori
tcell
provid
lifelong
immun
efficaci
rate
approxim
one
administr
two
administr
viru
replic
cytoplasm
henc
possibl
viral
genom
integr
host
genom
thank
nonseg
negativesens
rna
genom
genom
recombin
possibl
observ
virus
furthermor
mv
vaccin
current
produc
larg
scale
mani
countri
global
distribut
low
cost
epi
therefor
mv
vector
platform
provid
mean
rapidli
gener
potent
vaccin
candid
broad
spectrum
epidem
diseas
target
access
manufactur
process
provid
mean
rapidli
scaleup
vaccin
low
cost
stockpil
purpos
rapid
respons
vaccin
countermeasur
epidem
threat
recombin
mv
vector
gener
attenu
mv
vaccin
strain
attract
choic
develop
vaccin
candid
viral
infect
due
helicoid
packag
genom
mv
vector
take
foreign
gene
kb
size
possibl
heterolog
protein
stabli
express
high
level
passag
rescu
recombin
virus
retain
growth
capabl
similar
origin
mv
strain
mv
deliveri
platform
develop
preclin
stage
clinic
proofofconcept
sever
indic
preclin
track
record
fast
effect
adapt
varieti
pathogen
mv
vector
immunogen
mice
nhp
induc
longterm
neutral
antibodi
cellular
immun
even
context
preexist
immun
vector
initi
pioneer
clone
fulllength
infecti
mv
achiev
group
billet
zurich
later
schwarz
strain
mv
clone
institut
pasteur
pari
commerci
approv
mostli
attenu
effici
wide
use
mv
vaccin
strain
gener
infecti
clone
fulllength
antigenom
viral
cdna
fig
clone
ptm
plasmid
control
rna
promot
dna
sequenc
contain
ggg
motif
hammerhead
hepat
delta
viral
ribozym
ad
facilit
accur
cleavag
viral
rna
ensur
product
fulllength
viral
rna
viru
produc
rescu
transfect
ptmmvschw
plasmid
togeth
plasmid
express
schwarz
mv
l
gene
transcompl
human
cell
cell
constitut
express
rna
polymeras
mv
n
mv
p
transfect
cell
cocultur
mv
permiss
cell
line
vero
chicken
embryon
fibroblast
plaqu
pick
seed
amplif
character
rescu
virus
cdna
clone
possess
sequenc
parent
schwarz
strain
demonstr
stabil
negativesens
genom
enabl
insert
foreign
antigen
sever
addit
transcript
unit
atu
base
mv
cisact
sequenc
introduc
ptmmvschw
variou
site
genom
clone
site
accommod
insert
kb
length
multipl
six
base
pair
respect
rule
six
essenti
measl
genom
replic
one
common
concern
regard
use
mv
vaccin
vector
preexist
immun
due
broad
coverag
mv
vaccin
human
popul
worldwid
howev
demonstr
recombin
mv
vaccin
induc
strong
immun
respons
even
previous
immun
anim
human
although
surpris
mv
properti
may
account
phenomenon
first
recombin
mv
replic
therefor
although
low
dose
use
vaccin
amplifi
vivo
upon
cell
infect
recombin
mv
express
measl
protein
well
heterolog
antigen
mv
particl
assembl
releas
cell
heterolog
antigen
either
secret
cell
express
cell
surfac
depend
natur
antigen
stimul
immun
respons
second
viru
deliv
antigen
directli
dendrit
cell
macrophag
b
cell
effect
antigen
present
cell
viral
particl
transmit
cell
cell
cell
contact
lastli
recent
shown
addit
antigen
express
replic
mv
vector
natur
adjuv
defect
interf
genom
produc
recombin
viru
contribut
robust
induct
interferon
confer
vaccin
efficaci
vaccin
technolog
platform
capac
address
challeng
rapid
vaccin
develop
combin
strong
safeti
immunogen
profil
demonstr
multipl
applic
abil
target
antigen
infecti
pathogen
preclin
clinic
set
robust
antigenindepend
scalabl
manufactur
process
sever
recombin
measl
vaccin
number
viral
pathogen
far
gener
test
anim
model
fig
target
pathogen
includ
hiv
west
nile
viru
wnv
dengu
viru
denv
hepat
b
viru
hbv
human
papilloma
viru
hpv
chikv
niv
respiratori
syncytia
viru
rsv
sarscov
merscov
influenza
viru
iav
unpublish
zikv
unpublish
lasv
unpublish
ebov
unpublish
preclin
immunogen
protect
lethal
challeng
shown
mice
nhp
wnv
chikv
sarscov
iav
zikv
lasv
case
zikv
chikv
recombin
vaccin
candid
success
complet
phase
clinic
trial
adult
last
progress
phase
ii
trial
chikungunya
viru
chikv
envelop
positivesens
singlestrand
rna
viru
famili
alphavirida
approxim
infect
patient
develop
debilit
chronic
polyarthralgia
last
month
even
year
initi
thought
african
viru
emerg
la
reunion
island
indian
ocean
infect
third
island
popul
spread
throughout
india
give
rise
indian
ocean
lineag
reemerg
caribbean
island
martiniqu
sinc
chikv
found
countri
america
africa
asia
europ
million
peopl
infect
mvbase
chikv
vaccin
develop
express
chikv
structur
gene
c
clone
clinic
isol
chikv
ecsa
strain
express
chikv
structur
gene
result
format
viruslik
particl
infect
vero
cell
preclin
studi
mice
show
full
protect
lethal
chikv
challeng
singl
immun
even
presenc
preexist
immun
vector
mvchikv
vaccin
candid
introduc
clinic
trial
themi
bioscienc
http
themisbio
com
immunogen
demonstr
phase
clinic
trial
seroconvers
rate
singl
inject
seroconvers
boost
day
month
apart
seriou
advers
reaction
observ
even
group
receiv
high
dose
tcid
display
mild
reaction
headach
flulik
symptom
mild
muscl
pain
similar
observ
control
standard
mv
vaccin
importantli
studi
demonstr
immun
respons
measl
chikv
vlp
dampen
previou
mv
immun
sinc
volunt
preimmun
measl
phase
ii
clinic
trial
ongo
volunt
austria
germani
eudract
addit
two
independ
phase
studi
initi
usa
nih
puerto
rico
dod
june
clinicaltrialsgov
success
mvchikv
thu
far
reaffirm
mv
vector
excel
platform
vaccin
develop
dengu
viru
denv
envelop
positivesens
singlestrand
rna
viru
famili
flavivirida
caus
tropic
diseas
endem
southeast
asia
latin
america
identifi
dengu
neglect
diseas
potenti
emerg
new
geograph
area
due
climat
chang
major
complic
dengu
infect
four
distinct
serotyp
viru
circul
first
denv
infect
host
acquir
lifelong
immun
particular
serotyp
provid
crossprotect
serotyp
rather
nonneutr
antibodi
enhanc
infect
cell
carri
fc
receptor
use
denv
host
cell
entri
phenomenon
call
antibodydepend
enhanc
ade
due
ade
complic
strategi
denv
vaccin
develop
focu
tetraval
vaccin
simultan
stimul
immun
respons
four
denv
serotyp
recent
licens
denv
vaccin
dengvaxia
cydtdv
tetraval
recombin
vaccin
complet
phase
clinic
trial
distribut
southeast
asia
south
america
howev
vaccin
pose
safeti
concern
associ
increas
risk
diseas
exacerb
recipi
previous
expos
denv
sanofi
pull
vaccin
philippin
recent
concern
vaccin
use
recommend
individu
prior
exposur
denv
given
limit
current
vaccin
option
still
explor
mvbase
tetraval
vaccin
candid
develop
well
denv
antigen
use
consist
domain
iii
e
glycoprotein
ediii
four
serotyp
contain
serotypespecif
neutral
epitop
fuse
ectodomain
membran
protein
ectodomain
essenti
immunogen
insert
tetraval
ediii
due
adjuv
properti
induct
proinflammatori
antivir
cytokin
chemokin
preclin
trial
reveal
immun
mice
macaqu
develop
neutral
antibodi
four
serotyp
unpublish
data
zika
viru
zikv
flaviviru
close
relat
denv
approxim
amino
acid
differ
compar
differ
four
denv
serotyp
zikv
first
identifi
among
human
primat
mosquito
zika
forest
uganda
emerg
southeast
asia
becam
larg
endem
tropic
region
first
massiv
outbreak
seen
yap
island
popul
becam
infect
diseas
reach
latin
america
major
outbreak
brazil
zikv
infect
share
common
symptom
arboviru
infect
fever
flulik
symptom
rash
brazilian
outbreak
around
half
case
exhibit
symptom
viru
could
detect
saliva
infect
individu
zikv
declar
emerg
public
health
concern
due
neurolog
complic
associ
guillain
barr
e
syndrom
report
french
polynesia
microcephali
newborn
report
brazil
congenit
zikv
syndrom
suggest
humantohuman
transmiss
sexual
intercours
breast
milk
placent
transfer
close
evolutionari
relationship
denv
ade
virus
report
vitro
sera
denvinfect
individu
facilit
zikv
infect
usual
nonpermiss
cell
although
confirm
human
phenomenon
could
complic
vaccin
develop
zikv
denv
vaccin
current
preclin
trial
includ
mvbase
vaccin
develop
clone
fulllength
prm
e
gene
prme
zikv
ptmmvschw
vector
vaccin
candid
highli
immunogen
confer
full
protect
mice
monkey
phase
clinic
trial
initi
themi
bioscienc
http
themisbiocom
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
envelop
positivesens
singlestrand
rna
virus
possess
genom
approxim
kb
size
respect
virus
thought
origin
bat
first
known
case
sar
occur
transmiss
palm
civet
foshan
china
novemb
spread
throughout
china
countri
talli
report
case
countri
due
global
effort
diseas
manag
outbreak
declar
juli
year
ten
year
first
sar
incid
merscov
emerg
saudi
arabia
case
aris
transmiss
dromedari
camel
human
merscov
observ
spread
person
person
like
sarscov
local
outbreak
aris
import
case
observ
south
korea
result
nosocomi
transmiss
singl
infect
travel
structur
spike
protein
cov
identifi
target
neutral
antibodi
consid
potenti
target
subunit
viral
vector
vaccin
develop
institut
pasteur
mvbase
vaccin
sarscov
develop
human
codonoptim
gene
encod
nativ
sarscov
solubl
form
insert
atu
p
sequenc
ptmmvschw
gene
insert
interfer
recombin
mv
growth
titer
vaccin
test
mice
found
induc
neutral
antibodi
immun
anim
protect
lethal
dose
sarscov
challeng
deliv
intranas
nativ
observ
potent
elicit
antibodi
solubl
counterpart
antibodi
found
possess
high
neutral
activ
sarscov
mv
higher
level
observ
suggest
respons
merscov
mvbase
vaccin
gener
use
modifi
edmonston
strain
backbon
carri
either
fulllength
solubl
merscov
p
gene
like
sarscov
version
vaccin
also
induc
neutral
antibodi
antigenspecif
cytotox
tcell
elispot
assay
intracellular
cytokin
stain
flow
cytometri
show
strong
increas
specif
cell
vaccin
mice
ex
vivo
restimul
antigen
well
posit
kill
assay
promis
result
thu
far
demonstr
mv
vector
great
potenti
sarscov
merscov
vaccin
develop
ebola
marburg
virus
ebov
marv
envelop
negativesens
singlestrand
rna
virus
filovirida
famili
respons
hemorrhag
fever
associ
high
fatal
rate
ebov
first
discov
congo
sudan
circul
gener
restrict
central
african
countri
sever
ebov
strain
marv
caus
frequent
outbreak
continu
caus
sporad
outbreak
reemerg
regularli
eastern
central
africa
decemb
howev
unpreced
outbreak
emerg
western
african
countri
guinea
caus
major
crisi
rapid
spread
within
countri
well
neighbor
sierra
leon
liberia
air
travel
led
import
case
mani
countri
us
spain
mali
uk
turn
ebov
epidem
global
public
health
emerg
document
indic
total
report
case
ebov
infect
report
death
concert
intern
effort
manag
stem
outbreak
ebov
outbreak
predict
persist
next
decad
recent
outbreak
reenerg
ebov
vaccin
develop
massiv
influx
fund
sever
vaccin
candid
place
acceler
develop
among
two
viralvector
vaccin
target
envelop
glycoprotein
gp
ebov
current
phase
iiiii
clinic
trial
first
vaccin
base
vesicular
stomat
viru
vsv
vector
express
ebov
zair
strain
gp
rvsvzebov
vector
base
cattl
viru
frequent
associ
human
infect
nhp
experi
demonstr
vaccin
protect
ebov
challeng
also
effect
postinfect
treatment
within
day
infect
drawback
rvsvzebov
vaccin
includ
unknown
durat
protect
possibl
advers
effect
depend
dose
use
phase
clinic
trial
abruptli
stop
due
seriou
joint
pain
dermat
howev
vaccin
proven
effect
limit
diseas
spread
implement
ring
vaccin
scheme
guinea
second
vaccin
candid
ebov
adenoviru
vector
ad
express
ebovgp
vaccin
vector
provid
benefit
nonpathogen
human
natur
control
immun
system
howev
first
gener
adbas
vaccin
reduc
effect
due
preexist
immun
later
overcom
use
chimpanze
adenoviru
strain
chad
regardless
preexist
immun
confer
longlast
immun
huad
chad
platform
requir
booster
deliv
heterolog
modifi
vaccinia
viru
ankara
mva
vector
primeboost
protocol
difficult
set
ebovemerg
countri
healthcar
system
weak
unavail
area
moreov
dose
requir
effici
protect
tcid
highli
challeng
task
manufactur
vaccin
million
individu
mv
vector
provid
attract
altern
vaccin
develop
circumv
possibl
safeti
issu
associ
rvsv
vector
manufactur
hurdl
complex
regimen
adv
vector
approach
particular
mv
abil
elicit
humor
cellular
respons
advantag
effici
protect
tcell
respons
shown
play
role
control
ebov
infect
probabl
instrument
maintain
longterm
memori
furthermor
larg
insert
capac
mv
vector
enabl
develop
combin
vaccin
ebov
marv
mv
express
differ
form
gp
ebov
zair
strain
current
test
immunogen
efficaci
nhp
model
institut
pasteur
lassa
viru
lasv
biseg
negativesens
singlestrand
rna
viru
famili
arenavirida
caus
hemorrhag
fever
human
natal
multimamm
rat
natur
reservoir
infect
occur
rodenttohuman
transmiss
humantohuman
spread
occur
direct
contact
infect
bodi
fluid
nosocomi
set
lassa
fever
caus
nonspecif
symptom
sever
case
vascular
leakag
multiorgan
failur
report
diseas
first
identifi
nigeria
detect
throughout
western
central
africa
within
decad
unlik
ebov
infect
lassa
fever
occur
annual
pose
major
threat
local
popul
travel
healthcar
worker
us
cdc
estim
lasv
caus
case
death
yearli
among
hemorrhag
fever
virus
lasv
caus
highest
global
burden
due
stabil
aerosol
transmiss
also
render
potenti
bioterror
threat
sever
virusbas
vector
includ
vsv
vaccinia
viru
yellow
fever
viru
carri
surfac
glycoprotein
complex
gpc
lasv
show
promis
immunolog
result
guinea
pig
nhp
model
nineti
percent
nhp
surviv
lethal
lasv
challeng
vaccin
vaccinialasvgp
studi
also
confirm
cellmedi
immun
respons
key
lasv
protect
howev
use
vacciniabas
vaccin
desir
high
hiv
preval
region
africa
still
unclear
whether
immunosuppress
individu
face
risk
increas
vaccinia
replic
gener
infect
hand
vector
express
lasvgpc
observ
exhibit
genet
instabl
antigen
due
vector
small
insert
capac
variou
version
glycoprotein
test
resolv
issu
loss
antigen
express
still
observ
five
passag
recombin
viru
mvbase
vaccin
current
develop
institut
pasteur
problem
antigen
instabl
due
high
insert
capac
vector
experi
macaqu
shown
great
efficaci
vaccin
candid
protect
anim
singl
immun
lethal
lasv
challeng
unpublish
data
nipah
viru
niv
henipaviru
paramyxovirida
famili
envelop
negativesens
singlestrand
rna
viru
caus
diseas
human
anim
reservoir
fruit
bat
transmiss
occur
contact
bat
saliva
urin
often
consumpt
contamin
fruit
date
palm
sap
diseas
first
emerg
fatal
case
acut
enceph
town
nipah
malaysia
follow
hundr
case
diseas
mortal
viru
reemerg
india
bangladesh
higher
fatal
rate
pig
act
amplifi
host
infect
caus
mostli
respiratori
symptom
known
bark
pig
diseas
direct
transmiss
infect
pig
human
report
addit
fact
number
infect
patient
never
came
contact
either
bat
pig
indic
occurr
humantohuman
transmiss
niv
vaccin
target
antigen
niv
fusion
protein
f
glycoprotein
g
surfac
protein
import
host
cell
attach
viral
entri
variou
immun
strategi
summar
previou
review
canarypox
viru
carri
f
g
develop
use
anim
show
protect
intranas
challeng
piglet
human
vaccin
vaccinia
viru
adenoviru
mv
vsv
use
viral
vector
vaccin
candid
elicit
specif
neutral
antibodi
protect
challeng
hamster
ferret
model
vsvnivg
demonstr
partial
protect
lethal
challeng
nhp
well
although
lesion
observ
brain
cell
suggest
viral
replic
central
nervou
system
mvbase
vaccin
involv
insert
niv
g
gene
edmonston
strainbas
vector
initi
immunogen
test
perform
hamster
show
full
protect
lethal
challeng
second
immun
nhp
model
monkey
vaccin
tcid
rmvnivg
one
booster
show
clinic
sign
challeng
niv
demonstr
full
protect
vaccin
monkey
rift
valley
fever
viru
rvfv
phleboviru
triseg
negativesens
singlestrand
rna
genom
transmit
sever
aed
spp
culex
spp
mosquito
livestock
human
infect
caus
acut
sever
diseas
rumin
fever
loss
appetit
abort
fetus
high
mortal
rate
newborn
anim
human
deadend
host
infect
result
febril
ill
approxim
infect
present
sever
symptom
enceph
hemorrhag
syndrom
first
appear
rift
valley
region
kenya
viru
isol
sever
major
outbreak
report
throughout
africa
first
appear
outsid
region
larg
outbreak
arabian
peninsula
three
segment
rvfv
genom
name
small
medium
larg
l
gene
two
envelop
glycoprotein
gn
gc
serv
receptorbind
protein
facilit
viru
attach
infect
render
target
vaccin
develop
subunit
vaccin
target
gn
gc
shown
elicit
specif
rvfv
neutral
antibodi
mani
vaccin
platform
use
develop
vaccin
candid
rvfv
licens
vaccin
human
avail
yet
anim
vaccin
includ
live
attenu
smithburn
inactiv
rvfv
africa
unfortun
diva
differenti
infect
vaccin
anim
vaccin
present
problem
export
livestock
product
among
vaccin
pipelin
clinic
trial
conduct
formalininactiv
attenu
vaccin
demonstr
seroconvers
longterm
protect
rvfv
anim
human
nevertheless
attenu
vaccin
retain
risk
revers
reassort
field
strain
mv
vector
yet
use
develop
rvfv
vaccin
consid
drawback
current
vaccin
option
candid
advantag
provid
strong
argument
pursu
approach
furthermor
mv
shown
infect
anim
receptor
without
requir
unpublish
make
platform
viabl
anim
vaccin
well
mv
platform
highli
flexibl
enabl
easi
modif
creat
replic
deliveri
vector
variou
protect
antigen
platform
benefit
advantag
live
attenu
vaccin
without
risk
drawback
plugandplay
properti
help
ensur
time
avail
prevent
vaccin
whenev
new
epidem
occur
platform
track
record
safeti
immunogen
relev
antigen
pathogen
wellestablish
product
process
allow
substanti
acceler
develop
timelin
variou
mvvector
vaccin
demonstr
solid
perform
earli
phase
clinic
trial
provid
proofofconcept
mv
platform
power
tool
fight
current
emerg
viral
pathogen
